To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants with Symptomatic COPD

Trial Identifier: 217658
Sponsor: GlaxoSmithKline
Start Date: October 2022
Primary Completion Date: September 2023
Study Completion Date: September 2023
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Dongguan, China, 523326